Enapotamab vedotin Antibody

SKU: orb2302552

Description

Enapotamab vedotin is an investigational AXL-targeting antibody-drug conjugate (ADC) delivering MMAE to disrupt microtubules. It shows potent activity in preclinical models of high-AXL NSCLC, including EGFR inhibitor-resistant tumors, supporting its study in both in vitro and in vivo oncology research.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1912424-97-5
• MW: 150.63 kDa
• Purity: 95.00%
• Target: TAM Receptor,Antibody-Drug Conjugates (ADCs)

Bioactivity

• In Vivo:
  Methods: Enapotamab vedotin (2-4 mg/kg, intravenous injection, twice weekly) was used to treat LU1868 or LU0858 xenograft mouse models or AXL-overexpressing non-small cell lung cancer (NSCLC) models (e.g., LU0395) to observe its anti-tumor effects. Results: Enapotamab vedotin showed anti-tumor efficacy against AXL-overexpressing non-small cell lung cancer (NSCLC) models (e.g., LU0395) and showed resistance to EGFR inhibitors in LU1868 or LU0858 xenograft mouse models .
• In Vitro:
  Enapotamab vedotin (0-10 μg/mL, 5 days) treatment of AXL-overexpressing cells (ER20 and H1975-OR2) can reduce cell viability and produce cytotoxic effects.

Storage & Handling

• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

HuMAX-AXL-ADC, EnaV, EnaV, HuMAX-AXL-ADC

Quick Database Links

Gene Symbol

TAM Receptor,Antibody-Drug Conjugates (ADCs)